FDA 483 - Sterlab - June 10, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Sterlab, a medical device manufacturer in Vallauris, France, received a Form FDA-483 with two observations following an inspection. The firm's corrective and preventive action (CAPA) procedures were found to be inadequately established, with issues in investigations, documentation, and implementation. Additionally, Sterlab lacked adequate process control procedures, specifically for quality control testing of sealed pouches and proper identification during processing to prevent mix-ups.
ID · 2f5d1ec2-1cd0-4c24-a1a6-3319a29a1294